000130732 001__ 130732
000130732 005__ 20240228143457.0
000130732 0247_ $$2doi$$a10.1016/j.ccell.2015.12.003
000130732 0247_ $$2pmid$$apmid:26766587
000130732 0247_ $$2pmc$$apmc:PMC4714043
000130732 0247_ $$2ISSN$$a1535-6108
000130732 0247_ $$2ISSN$$a1878-3686
000130732 0247_ $$2altmetric$$aaltmetric:4980160
000130732 037__ $$aDKFZ-2017-05810
000130732 041__ $$aeng
000130732 082__ $$a610
000130732 1001_ $$aVo, BaoHan T$$b0
000130732 245__ $$aThe Interaction of Myc with Miz1 Defines Medulloblastoma Subgroup Identity.
000130732 260__ $$aCambridge, Mass.$$bCell Press$$c2016
000130732 3367_ $$2DRIVER$$aarticle
000130732 3367_ $$2DataCite$$aOutput Types/Journal article
000130732 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1522150577_18537
000130732 3367_ $$2BibTeX$$aARTICLE
000130732 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000130732 3367_ $$00$$2EndNote$$aJournal Article
000130732 520__ $$aFour distinct subgroups of cerebellar medulloblastomas (MBs) differ in their histopathology, molecular profiles, and prognosis. c-Myc (Myc) or MycN overexpression in granule neuron progenitors (GNPs) induces Group 3 (G3) or Sonic Hedgehog (SHH) MBs, respectively. Differences in Myc and MycN transcriptional profiles depend, in part, on their interaction with Miz1, which binds strongly to Myc but not MycN, to target sites on chromatin. Myc suppresses ciliogenesis and reprograms the transcriptome of SHH-dependent GNPs through Miz1-dependent gene repression to maintain stemness. Genetic disruption of the Myc/Miz1 interaction inhibited G3 MB development. Target genes of Myc/Miz1 are repressed in human G3 MBs but not in other subgroups. Therefore, the Myc/Miz1 interaction is a defining hallmark of G3 MB development.
000130732 536__ $$0G:(DE-HGF)POF3-312$$a312 - Functional and structural genomics (POF3-312)$$cPOF3-312$$fPOF III$$x0
000130732 588__ $$aDataset connected to CrossRef, PubMed,
000130732 650_7 $$2NLM Chemicals$$aHedgehog Proteins
000130732 650_7 $$2NLM Chemicals$$aMiz1 protein, mouse
000130732 650_7 $$2NLM Chemicals$$aNuclear Proteins
000130732 650_7 $$2NLM Chemicals$$aProtein Inhibitors of Activated STAT
000130732 650_7 $$2NLM Chemicals$$aProto-Oncogene Proteins c-myc
000130732 7001_ $$aWolf, Elmar$$b1
000130732 7001_ $$0P:(DE-He78)0ac2bd1a9fb1823a351ee4434d80808b$$aKawauchi, Daisuke$$b2$$udkfz
000130732 7001_ $$aGebhardt, Anneli$$b3
000130732 7001_ $$aRehg, Jerold E$$b4
000130732 7001_ $$aFinkelstein, David$$b5
000130732 7001_ $$aWalz, Susanne$$b6
000130732 7001_ $$aMurphy, Brian L$$b7
000130732 7001_ $$aYoun, Yong Ha$$b8
000130732 7001_ $$aHan, Young-Goo$$b9
000130732 7001_ $$aEilers, Martin$$b10
000130732 7001_ $$aRoussel, Martine F$$b11
000130732 773__ $$0PERI:(DE-600)2074034-7$$a10.1016/j.ccell.2015.12.003$$gVol. 29, no. 1, p. 5 - 16$$n1$$p5 - 16$$tCancer cell$$v29$$x1535-6108$$y2016
000130732 909CO $$ooai:inrepo02.dkfz.de:130732$$pVDB
000130732 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)0ac2bd1a9fb1823a351ee4434d80808b$$aDeutsches Krebsforschungszentrum$$b2$$kDKFZ
000130732 9131_ $$0G:(DE-HGF)POF3-312$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vFunctional and structural genomics$$x0
000130732 9141_ $$y2016
000130732 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bCANCER CELL : 2015
000130732 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000130732 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000130732 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000130732 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search
000130732 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC
000130732 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bThomson Reuters Master Journal List
000130732 915__ $$0StatID:(DE-HGF)0110$$2StatID$$aWoS$$bScience Citation Index
000130732 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000130732 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000130732 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine
000130732 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences
000130732 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews
000130732 915__ $$0StatID:(DE-HGF)9920$$2StatID$$aIF >= 20$$bCANCER CELL : 2015
000130732 9201_ $$0I:(DE-He78)B062-20160331$$kB062$$lPädiatrische Neuroonkologie$$x0
000130732 980__ $$ajournal
000130732 980__ $$aVDB
000130732 980__ $$aI:(DE-He78)B062-20160331
000130732 980__ $$aUNRESTRICTED